3 ms·
> I would be wary about trusting current FDA oversight and governance implementations overseas, especially in India due to geopolitical concerns (prioritizing t
by alephnerd 3y ago
> I would be wary about trusting current FDA oversight and governance implementations overseas, especially in India due to geopolitical concerns (prioritizing the relationship over robust testing).
I have family that work in the Pharma Manufacturing Industry in India. If you've ever taken a generic drug, it's likely manufactured in a factory within 20 miles of my ancestral village.
The US FDA does NOT compromise on testing in India and China. They will send US FDA inspectors to factories on random audits.
There is stuff to complain about w/ regards to the US, but the US FDA is pretty good at safety globally. The only better regulatory agencies I can think of is the EU's EMA and SK's KFDA.
- iudqnolq 3y agoAs the article you're responding to details in one case FDA inspectors literally saw employees frantically destroying documents as they walked in. That factory was allowed to continue producing drugs. Empirical tests have shown certain factories manufactured drugs with insufficient concentration of the active ingredient. Those drugs are still on the market.
- alephnerd 3y agoValisure isn't a drug. It's regulated by the "Food Safety" division of the FDA. The FDA as an organization over-specializes on Biologics and Drug regulation at the expense of Food Regulation [0][1] and due to the "Food Safety" division's overlap with USDA. [0] - https://www.fda.gov/about-fda/fda-organization/fda-organization-charts https://www.fda.gov/about-fda/fda-organization/fda-organizat... [1] - https://www.politico.com/interactives/2022/fda-fails-regulate-food-health-safety-hazards/ https://www.politico.com/interactives/2022/fda-fails-regulat...
- iudqnolq 3y agoOf course Valisure isn't a drug. Valisure is the lab that tested the drug. What does that have to do wit- what I said?
- alephnerd 3y agoBECAUSE THE PORTION OF THE FDA THAT REFULATES DRUGS IS A DIFFERENT ORGANIZATION FROM THE ONE IN THE EXAMPLE YOU MENTIONED. I am talking about drug and biologics regulation. Not food safety.
- iudqnolq 3y agoValisure conducted a test of a regulated drug. Based on the results of Valisure's test we know the drug wasn't strong enough. That provides an example of an issue the current drug regulatatory scheme failed to catch. That suggests a problem with the current drug regulatory scheme. I don't know why you're talking about food safety.
- jqpabc123 3y agoEmpirical tests have shown certain factories manufactured drugs with insufficient concentration of the active ingredient. Basically, they are making more profit by selling a placebo. This is often the case with low cost generics. When the low cost generics are ineffective, doctors prescribe more expensive alternatives produced by the same manufacturer --- again they generate more profit.
- thaumasiotes 3y ago> The US FDA does NOT compromise on testing in India and China. Counterpoint: https://web.archive.org/web/20130815013650/http://features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor/ https://web.archive.org/web/20130815013650/http://features.b... They compromise quite a bit, considering a multi-billion dollar company was found, many years down the line, to be completely fraudulent.
- alephnerd 3y agoRanbaxy collapsed in 2014 due to their constant failures with the FDA [0]. Daiichi Sankyo, the largest owner in Ranbaxy, sold their stake at a loss to Sun Pharma in 2014. The article you linked was the icing on the cake before the Ranbaxy scandal. In fact, it was Ranbaxy's massive shitshow that caused the US to open an FDA Field Office in India (specifically in our hick ass area of Himachal) [0] - https://www.biospectrumasia.com/opinion/25/3716/ranbaxys-fall-from-grace-.html https://www.biospectrumasia.com/opinion/25/3716/ranbaxys-fal...
- thaumasiotes 3y ago> Ranbaxy collapsed in 2014 due to their constant failures with the FDA [0]. Your link [0] doesn't actually support that claim, for the obvious reason that it isn't true. Ranbaxy didn't experience failures with the FDA. They had a stream of neverending successes punctuated by a years-long investigation that was triggered when a whistleblower emailed the FDA to reveal that Ranbaxy's data, and products, were all fraudulent. Note that despite the whistleblower's accusations proving to be completely correct, the company did not collapse. It was acquired for a significant price. > Well before the final resolution, in November 2011, the FDA gave its final blessing for Ranbaxy’s version of Lipitor. Asked about the decision to allow Ranbaxy to make Lipitor after its misconduct at two plants was revealed, an FDA spokesman asserts that the agency is required to evaluate a drug application on a “facility-specific basis.” The company’s “data integrity problems,” he says, occurred at facilities different from where its generic Lipitor is manufactured. > That’s true — but it leaves out the fact that Ranbaxy originally applied to make Lipitor at one of its Indian facilities, which was then blacklisted by the FDA. The agency permitted the company to make a significant shift in its application: to switch the plant at which it would make the generic Lipitor. Ranbaxy now proposed making the drug in the U.S. at a facility that was not under FDA investigation. > Last November [2012], Ranbaxy was back in the headlines with some very unwelcome news — the company had detected tiny glass particles in its Lipitor. It had to recall millions of pills and temporarily halt production. Says the FDA spokesperson, “The fact that there were some quality problems that led to a limited recall of the generic product was not a result of the approval process or how it was handled.” I would not call the FDA a model of efficiency, competence, basic common sense, or honesty. But then again, maybe the problem was the lack of an FDA Field Office in the US.